Click here for Bosulif®▼ (bosutinib monohydrate) Prescribing Information. Adverse event reporting information can be found at the bottom of the page.
y-axis: AE, x-axis: patients, %
*Patients who received one or more doses of study drug for either newly diagnosed CP CML or were resistant or intolerant to prior therapy with CP, AP, BP CML or Ph+ ALL.
The data shown includes real-world data in addition to safety data from the BFORE trial and Study 200.
*Patients who received one or more doses of study drug.
Please refer to the BOSULIF SmPC for full details of adverse events
If you still require further information, please contact Medical Information
Hear views from the MDT: Rebecca Hallam (nurse) and Andrea Preston (pharmacy) on how to support patients through their treatment
Hear from Dr Lina Eliasson on managing adherance with TKIs and fatigue
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-2688. December 2020